Sideline Gold on Fe...
Health Care: Drugs
Synergy Pharmaceuticals Inc. (SGYP: NASDAQ)
$4.96 0.19 | 3.98%
06/18/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 4.77 |
| 52 Week High | 7.44 |
| 52 Week Low | 2.98 |
| Avg. Daily Vol. (Mil) | 1.17 |
| Beta (3 year) | 0.72 |
| Share Related Items | |
| Mkt Cap (Mil) | 430.17 |
| Shares Out (Mil) | 90.18 |
| Float (Mil) | 64.51 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.30 |
| Current Ratio | 2.40 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 0.00 |
| Price/Book | 59.34 |
| Price/Cash Flow | -8.40 |
| Per Share Data | |
| Earnings | -0.76 |
| Sales | 0.00 |
| Book Value | 0.08 |
| Cash Flow | -0.57 |
| Business Summary | |
|---|---|
| Synergy Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. Its lead product candidate is plecanatide. | |
| General Information | |
| 420 Lexington Avenue
Suite 1609 New York, NY 10170 |
|
| www.synergybio.net | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 18 | |
| CEO: Gary S. Jacob | |
| Short Interest | |
| Current Month (Mil) | 6.13 |
| Previous Month (Mil) | 5.01 |
| Short Interest Ratio (Days) | 6.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -223.30 |
| Return on Investments | -705.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with SGYP
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- UserGopher Gold
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- Userpoore mans portfolio
Latest SGYP Headlines from TheStreet
- Synergy Pharmaceuticals Announces Change In Presentation Time At Jefferies 2013 Global Healthcare Conference 06.03.13 | 10:06 am
- Synergy Pharmaceuticals To Present At Jefferies 2013 Global Healthcare Conference 05.31.13 | 06:05 am
- Synergy Pharmaceuticals Added To The MSCI Global Small Cap Indices 05.30.13 | 06:05 am
- Synergy Pharmaceuticals Appoints Patrick H. Griffin, M.D. As Chief Medical Officer 05.29.13 | 04:05 pm
- Synergy Pharmaceuticals Presents Plecanatide Results From A Large Multicenter Clinical Study At Late-Breaking Abstract Session During Digestive Disease Week 2013 05.21.13 | 10:05 am
- Synergy Pharmaceuticals Added To NASDAQ Biotechnology Index 05.14.13 | 08:05 am
- Synergy Pharmaceuticals Reports First Quarter 2013 Financial Results 05.09.13 | 05:05 pm
- Synergy Pharmaceuticals' Chief Scientific Officer To Give Plenary Lecture On Plecanatide And SP-333 At The 15th Annual TIDES Summit 05.09.13 | 08:05 am
- Synergy Pharmaceuticals Becomes Oversold (SGYP) 04.23.13 | 04:04 pm
- Synergy Pharmaceuticals Announces Closing Of Public Offering Of Shares Of Common Stock 04.16.13 | 11:04 am
Press Releases for SGYP
- Synergy Pharmaceuticals To Present Scientific Posters At The Upcoming Gastroenterology Society Meetings In The U.S. And Europe - PR Newswire 07.31.12 | 12:07 pm
- Synergy Pharmaceuticals To Present At 14th Annual BIO CEO & Investor Conference - Business Wire 02.09.12 | 08:02 am
- Synergy Pharmaceuticals Engages The Trout Group For Investor Relations Services - Business Wire 02.08.12 | 08:02 am
- European Patent Office Upholds Synergy Pharmaceuticals’ Grant Of Claims To Plecanatide - Business Wire 01.04.12 | 06:01 am
- Synergy Pharmaceuticals Announces Full Exercise Of Over-Allotment Option By Aegis Capital Corp. - Business Wire 12.13.11 | 04:12 pm
- Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. And Its Chief Scientific Officer And Senior VP Of R&D, Dr. Mark G. Currie - Business Wire 12.13.11 | 03:12 am
- Synergy Pharmaceuticals Inc. Announces Pricing Of Public Offering Of 1,875,000 Units, Listing On NASDAQ And Effectiveness Of Reverse Stock Split - Business Wire 12.01.11 | 08:12 am
- Synergy Pharmaceuticals Raises $5.64 Million In Financing - Business Wire 11.15.11 | 05:11 am
- Synergy Pharmaceuticals And Fox Chase Cancer Center Presentation At 2011 ACG Meeting Highlights Potential Of GC-C Agonists To Delay Progression Of Colitis Into Colon Cancer - Business Wire 10.31.11 | 06:10 am
- Synergy Pharmaceuticals Initiates Dosing Of Patients In Phase II/III Trial Of Plecanatide In Chronic Constipation - Business Wire 10.24.11 | 06:10 am
Partner Headlines for SGYP
- 5 Healthcare Companies With Recent Insider Buying - Seeking Alpha 11.18.12 | 09:11 am
- IND Submission by Synergy Pharma - Analyst Blog - NASDAQ 09.17.12 | 09:09 pm
- Synergy Acquires FV-100 from BMY - Analyst Blog - NASDAQ 08.28.12 | 10:08 pm
- Synergy Acquires FV-100 from BMY - Analyst Blog - Zacks 08.28.12 | 06:08 pm
- Key Appointment Marks Another Win For Synergy Pharmaceuticals - Seeking Alpha 05.03.12 | 09:05 am
